To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin
Read time: 1 minute
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma.
Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of Hodgkin lymphoma. The data were featured during a press briefing at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL and will be presented during an oral session on Monday, December 6, 2010, at 7:00 a.m. Eastern Time.
Key findings from the trial in 102 relapsed or refractory Hodgkin lymphoma patients included:
• 75 percent of patients achieved an objective response as assessed by an independent central review using the stringent Cheson 2007 criteria, the primary endpoint of the trial.
• 34 percent of patients achieved a complete remission.
• The median duration of response was 29 weeks by independent central review and 47 weeks by investigator assessment.
• Among patients achieving a complete remission, the median duration of response had not yet been reached at a median follow-up of approximately one year.
• Tumor reductions were achieved in 94 percent of patients.
• Brentuximab vedotin treatment was associated with manageable adverse events, with the most common being peripheral sensory neuropathy, fatigue, nausea, upper respiratory tract infection and diarrhea. The most common Grade 3 or higher adverse events were neutropenia, peripheral sensory neuropathy, thrombocytopenia and anemia.
"Up to thirty percent of all patients diagnosed with Hodgkin lymphoma will relapse. These patients have limited treatment options beyond autologous stem cell transplantation and represent a significant unmet medical need," said Dr. Robert Chen, Assistant Professor, Hematology & Hematopoietic Cell Transplantation at City of Hope. "Based on these data, brentuximab vedotin has the potential to change the treatment paradigm for relapsed or refractory Hodgkin lymphoma patients, and could be the first treatment approved for these patients in more than 20 years."
"I have rarely seen such response rates in this relapsed or refractory disease population," said Dr. Andreas Engert, Professor of Internal Medicine, University of Cologne, Germany. "These data highlight brentuximab vedotin as a potential addition to the treatment options for Hodgkin lymphoma patients."
Based on recent discussions with the U.S. Food and Drug Administration (FDA), Seattle Genetics plans to submit a Biologics License Application (BLA) in the first quarter of 2011 to seek approval for both relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of Hodgkin lymphoma. The data were featured during a press briefing at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL and will be presented during an oral session on Monday, December 6, 2010, at 7:00 a.m. Eastern Time.
Key findings from the trial in 102 relapsed or refractory Hodgkin lymphoma patients included:
• 75 percent of patients achieved an objective response as assessed by an independent central review using the stringent Cheson 2007 criteria, the primary endpoint of the trial.
• 34 percent of patients achieved a complete remission.
• The median duration of response was 29 weeks by independent central review and 47 weeks by investigator assessment.
• Among patients achieving a complete remission, the median duration of response had not yet been reached at a median follow-up of approximately one year.
• Tumor reductions were achieved in 94 percent of patients.
• Brentuximab vedotin treatment was associated with manageable adverse events, with the most common being peripheral sensory neuropathy, fatigue, nausea, upper respiratory tract infection and diarrhea. The most common Grade 3 or higher adverse events were neutropenia, peripheral sensory neuropathy, thrombocytopenia and anemia.
"Up to thirty percent of all patients diagnosed with Hodgkin lymphoma will relapse. These patients have limited treatment options beyond autologous stem cell transplantation and represent a significant unmet medical need," said Dr. Robert Chen, Assistant Professor, Hematology & Hematopoietic Cell Transplantation at City of Hope. "Based on these data, brentuximab vedotin has the potential to change the treatment paradigm for relapsed or refractory Hodgkin lymphoma patients, and could be the first treatment approved for these patients in more than 20 years."
"I have rarely seen such response rates in this relapsed or refractory disease population," said Dr. Andreas Engert, Professor of Internal Medicine, University of Cologne, Germany. "These data highlight brentuximab vedotin as a potential addition to the treatment options for Hodgkin lymphoma patients."
Based on recent discussions with the U.S. Food and Drug Administration (FDA), Seattle Genetics plans to submit a Biologics License Application (BLA) in the first quarter of 2011 to seek approval for both relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
